Figure 6 | Scientific Reports

Figure 6

From: Predicting treatment outcomes of intravitreal brolucizumab for polypoidal choroidal vasculopathy through noninvasive assessment of polypoidal lesion blood flow with optical coherence tomography angiography

Figure 6

Images of the right eye of a 69-year-old man with polypoidal choroidal vasculopathy in the group showing persistence of blood flow signals within polypoidal lesions. (a–f) Baseline. Best corrected-visual acuity (BCVA) of the right eye is − 0.08 logarithm of the minimal angle of resolution (logMAR) units. (a) Color fundus photograph shows an orange-red lesion accompanied by subretinal hemorrhage. (b) Indocyanine green angiography (ICGA) shows a polypoidal lesion with a branching neovascular network (BVN). (c) Optical coherence tomography (OCT) B-scan image through the fovea shows a sharp-peaked and shallow irregular pigment epithelial detachment (PED) with serous retinal detachment (SRD). (d) Optical coherence tomography angiography (OCTA) en face image shows blood flow signals corresponding to the polypoidal lesion and the BVN. (e, f) OCTA B-scan images (e: horizontal, f: vertical) show blood flow signals within the PED corresponding to the polypoidal lesion (arrowheads). (gl) 3 months after the initial treatment. BCVA of the right eye is − 0.08 logMAR units. (g) Color fundus photograph shows no subretinal hemorrhage. (h) ICGA shows complete regression of the polypoidal lesion. (i) OCT B-scan shows the sharp-peaked PED to be diminished without SRD. (j) OCTA en face image shows unclear blood flow signals within the polypoidal lesion. (k, l) OCTA B-scan images (k: horizontal, l: vertical) show blood flow signals within the PED corresponding to the polypoidal lesion (arrowheads). (m–o) 6 months after the initial treatment. BCVA of the right eye is − 0.08 logMAR units. (m) Color fundus photograph shows no subretinal hemorrhage. (n, o) OCT B-scan images through the fovea (n: horizontal, o: vertical) show SRD recurrence and an enlargement of the sharp-peaked PED. In total, 8 injections were required during the 1-year study period due to SRD recurrence.

Back to article page